Virus Production for Clinical Gene Therapy

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Citations (Scopus)


Gene therapy is becoming increasingly relevant for the treatment of prominent human diseases. Viral vectors are currently used in more than 50% of the gene therapy clinical trials, most of them aimed at cancer diseases. Clearly, the increasing needs of high-quality viral preparations required the elimination of process bottlenecks, streamlining the development of the viral into a real-world clinical tool . Virus production for clinical gene therapy can be a limiting step because many virus generation protocols rely on labor-intensive, bench-scale methods; robust, cost-effective strategies for the delivery of clinical-grade viruses are thus essential for the future of gene therapy. A comprehensive picture of key aspects on the integration of upstream and downstream processing is addressed in this chapter, by describing the case study of recombinant budded baculoviruses for gene therapy; scalable methods are described in detail as well as mandatory characterization techniques for a proper and complete quality assessment of the viral vectors.
Original languageUnknown
Title of host publicationGene therapy of cancer: methods and protocols
EditorsW. Walther, U.S. Stein
Place of PublicationNew York
PublisherHumana Press
ISBN (Print)978-1-934115-85-5/978-1-59745-561-9
Publication statusPublished - 1 Jan 2009

Publication series

NameMethods in Molecular Biology
PublisherHumana Press
ISSN (Print)1064-3745

Cite this

Carrondo, M. J. T., & Alves, P. M. (2009). Virus Production for Clinical Gene Therapy. In W. Walther, & U. S. Stein (Eds.), Gene therapy of cancer: methods and protocols (pp. 447-470). (Methods in Molecular Biology; No. 542). New York: Humana Press.